Regulatory alerts
COVID-19 Vaccine AstraZeneca and thromboembolic events with concurrent low platelets – revisions to product information
The MHRA has issued a notification to inform of revisions to the COVID-19 Vaccine AstraZeneca product information for healthcare professionals.
![National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [v2]](https://images.zapnito.com/users/336911/documents/116395/ce722730-0f62-44d7-9eb6-55117d523204-med.jpg)
![National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [V3]](https://images.zapnito.com/users/336911/documents/116397/f7d9010a-6bf6-46b1-ab47-c0c584a49bae-med.jpg)
![Standard operating procedure (SOP) for general practice in the context of coronavirus (COVID-19) [v4.2]](https://images.zapnito.com/users/336911/documents/116418/5cabc9b7-e3ab-48f0-955d-04060b1b4961-med.jpg)
SMC accepts acalabrutinib for chronic lymphocytic leukaemia (restricted use)
Acalabrutinib is recommended as monotherapy under two indications.
SMC accepts treatment for relapsed and refractory multiple myeloma (restricted use)
Isatuximab accepted in combination with pomalidomide and dexamethasone for patients receiving fourth-line therapy.
SMC accepts dapagliflozin for chronic heart failure with reduced ejection fraction
Research has shown that dapagliflozin demonstrated a significant reduction in the composite outcome of hospitalisation for heart failure, urgent heart failure visit and cardiovascular death compared with placebo.
SMC accepts galcanezumab for the prophylaxis of migraine (restricted use)
Studies in patients with episodic and chronic migraine have shown that galcanezumab significantly reduced the number of migraine days per month compared with placebo.
SMC accepts asthma treatment dupilumab (restricted use)
Dupilumab accepted as an add-on maintenance treatment in severe asthma.
